Loading...
•
Dec 31, 2022
Ultragenyx Q4 2022 Earnings Report
Ultragenyx reported Q4 2022 financial results with total revenue of $103.3 million, driven by Crysvita and Dojolvi sales, and provided 2023 revenue guidance.
Key Takeaways
Ultragenyx reported Q4 2022 total revenue of $103.3 million. The company reaffirmed its 2023 financial guidance, expecting total revenue between $425 million and $450 million and net cash used in operations to be less than $400 million.
Total revenue for Q4 2022 was $103.3 million.
Crysvita revenue in Ultragenyx territories was $74.6 million, including $66.9 million in North America collaboration revenue.
Dojolvi revenue was $16.4 million in Q4 2022.
Mepsevii revenue was $4.8 million in Q4 2022.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
Ultragenyx reaffirms its financial guidance for the full year 2023.
Positive Outlook
- Total revenue in the range of $425 million to $450 million
- Crysvita revenue in the range of $325 million to $340 million, including royalties in Europe and North America.
- Dojolvi revenue in the range of $65 million to $75 million
- Net Cash Used in Operations is expected to be less than $400 million
- Phase 2/3 study dosing patients; Phase 2 enrollment complete, data expected in mid-2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income